title: [Medical treatment of prostate cancer].
abstract: Hormone dependence of prostate cancer is well known. In 80% of cases with metastases, hormone suppression leads to the reduction of tumour volume and related disorders. However the treatment is generally palliative because malignant process recurs after about around 16 months. Mean survival is less than 3 years in these forms. Lack of response come always together with a poor prognosis, and there is 90% mortality at 2 years. Advanced prostatic cancer should not be treated with hormones if the patient has few symptoms and his quality of life is satisfactory. Symptomatic forms require hormone manipulation. Orchidectomy or LH-RH are recommended. Total androgen ablation (combined treatment) leads rapidly to more relief of symptoms, but its drawbacks and especially high cost indicate that its use should be weighed individually. Estramustine is not a first-lune treatment. Presently, there is no criteria to predict response to treatment.
authors.affiliation: Service d'urologie, centre hospitalier régional et universitaire Pontchaillou, Rennes.
authors.forename: B
authors.initials: B
authors.lastname: Lobel
authors.forename: B
authors.initials: B
authors.lastname: Cipolla
authors.forename: J
authors.initials: J
authors.lastname: Labrador
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D006728:Hormones
vernacular_title: Traitement médical du cancer de la prostate.